MDMA08 ;;;;;;;;;;.pdf

(228 KB) Pobierz
Infofacts
MDMA (Ecstasy)
MDMA (3,4 methylenedioxymethamphet-
amine) is a synthetic, psychoactive drug
that is chemically similar to the stimulant
methamphetamine and the hallucinogen
mescaline. It produces an energizing
effect as well as feelings of euphoria,
emotional warmth, and distortions in time
perception and tactile experiences.
(or space between adjacent neurons)
when the signal between neurons needs
to be terminated. MDMA also causes
excessive release of serotonin and has
similar but less potent effects on neurons
that contain dopamine and norepineph-
rine. The serotonin system plays an
important role in regulating mood,
aggression, sexual activity, sleep, and
sensitivity to pain.
How is MDMA Abused?
MDMA is taken orally as a capsule or
tablet. It was initially popular among
white adolescents and young adults in
the nightclub scene or at weekend-long
dance parties known as raves. However,
the profile of the typical MDMA user has
changed, and the drug now affects a
broader range of ethnic groups. MDMA
is also popular among urban gay
males—some report using MDMA as
part of a multiple-drug experience that
includes marijuana, cocaine, metham-
phetamine, ketamine, and other legal
and illegal substances.
MDMA can produce confusion, depres-
sion, sleep problems, drug craving, and
severe anxiety. These problems can
occur soon after taking the drug or,
sometimes, even days or weeks after tak-
ing MDMA. In addition, chronic users of
MDMA perform more poorly than
nonusers on certain types of cognitive or
memory tasks, although some of these
effects may be due to the use of other
drugs in combination with MDMA.
Research in animals indicates that
MDMA can be harmful to the brain—
one study in nonhuman primates showed
that exposure to MDMA for only 4 days
caused damage to serotonin nerve termi-
nals that was still evident 6 to 7 years
later. 1 Although similar neurotoxicity has
not been shown definitively in humans,
the wealth of animal research indicating
MDMA’s damaging properties strongly
suggests that MDMA is not a safe drug
for human consumption. This is currently
an area of active research.
How does MDMA Affect
the Brain?
MDMA exerts its primary effects in the
brain on neurons that use the chemical
serotonin to communicate with other
neurons. MDMA binds to the serotonin
transporter, which is responsible for
removing serotonin from the synapse
August 2008
Page 1 of 4
423203676.051.png 423203676.062.png 423203676.066.png 423203676.067.png 423203676.001.png 423203676.002.png 423203676.003.png 423203676.004.png 423203676.005.png 423203676.006.png 423203676.007.png
Addictive Potential
For some people, MDMA can be addic-
tive. 2 A survey of young adult and
adolescent MDMA users found that 43
percent of those who reported ecstasy
use met the accepted diagnostic criteria
for dependence, as evidenced by contin-
ued use despite knowledge of physical
or psychological harm, withdrawal
effects, and tolerance (or diminished
response). 3 These results are consistent
with those of similar studies in other
countries that also suggest a high rate
of MDMA dependence among users. 4
MDMA abstinence-associated withdrawal
symptoms include fatigue, loss of
appetite, depressed feelings, and
trouble concentrating. 2
sions, this can lead to a sharp increase
in body temperature (hyperthermia),
which can result in liver, kidney, and
cardiovascular system failure, and
death. MDMA can interfere with its
own metabolism (breakdown within
the body); therefore, potentially harmful
levels can be reached by repeated
MDMA administration within short
periods of time.
Other drugs that are chemically similar
to MDMA, such as MDA (methylene-
dioxyamphetamine, the parent drug of
MDMA) and PMA (paramethoxyamphet-
amine, associated with fatalities in the
United States and Australia), 5 are some-
times also sold as ecstasy. These drugs
can be neurotoxic or create additional
health risks to the user. Furthermore,
ecstasy tablets may be adulterated with
other substances, such as ephedrine
(a stimulant); dextromethorphan (DXM,
a cough suppressant); ketamine (an
anesthetic used mostly by veterinarians);
caffeine; cocaine; and methampheta-
mine. Although the combination of
MDMA with one or more of these drugs
may be inherently dangerous, users
might also combine these with other sub-
stances such as marijuana and alcohol,
putting themselves at even higher risk.
What Other Adverse
Effects does MDMA
Have on Health?
MDMA can also be dangerous to over-
all health and, on rare occasions, lethal.
MDMA can have many of the same
physical effects as other stimulants such
as cocaine and amphetamines. These
include increases in heart rate and
blood pressure, which present risks of
particular concern for people with circu-
latory problems or heart disease; and
other symptoms such as muscle tension,
involuntary teeth clenching, nausea,
blurred vision, faintness, and chills
or sweating.
What Treatment
Options Exist?
There are no specific treatments for
MDMA abuse and addiction. The most
effective treatments for drug abuse and
addiction in general are cognitive-
In high doses, MDMA can interfere with
the body’s ability to regulate tempera-
ture. On rare but unpredictable occa-
August 2008
Page 2 of 4
423203676.008.png 423203676.009.png 423203676.010.png 423203676.011.png 423203676.012.png 423203676.013.png 423203676.014.png 423203676.015.png 423203676.016.png 423203676.017.png 423203676.018.png 423203676.019.png 423203676.020.png 423203676.021.png 423203676.022.png 423203676.023.png 423203676.024.png 423203676.025.png
behavioral interventions that are
designed to help modify the patient's
thinking, expectancies, and behaviors,
and to increase skills in coping with
life's stressors. Drug abuse recovery
support groups may be effective in com-
bination with behavioral interventions to
support long-term, drug-free recovery.
There are currently no pharmacological
treatments for addiction to MDMA.
For the third year in a row, the younger
students surveyed reported a slightly
weaker attitude about the risks associated
with MDMA use. The proportion of 8th-
graders who perceived risk of harm from
using MDMA “occasionally” decreased
significantly, from 52.0 percent in 2006
to 48.6 percent in 2007; this proportion
also fell significantly among 10th-
graders, from 71.3 percent in 2006 to
68.2 percent in 2007. Perceived risk of
MDMA use remained unchanged for
12th-graders from 2006 to 2007.
How Widespread is
MDMA Abuse?
Monitoring the Future (MTF)
Survey ††
Between 2005 and 2007, past-year
abuse of MDMA increased among 12th-
graders, from 3.0 percent to 4.5 per-
cent; and between 2004 and 2007,
past-year abuse of MDMA increased
among 10th-graders, from 2.4 percent
to 3.5 percent.
National Survey on Drug Use
and Health (NSDUH) ††††
In 2006, an estimated 528,000 people
(0.2 percent of the population) in the
United States age 12 or older used
MDMA in the month prior to being sur-
veyed. Lifetime use increased among
individuals aged 12 years or older, from
4.3 percent in 2002 to 5.0 percent in
2006; however, past-year use of ecstasy
decreased from 1.3 percent to 0.9 per-
cent during the same 5-year period.
Approximately 860,000 Americans
used ecstasy for the first time in 2006,
which is a significant increase from the
615,000 first-time users reported in
2005. Most (70.1 percent) of these new
users were 18 or older; and among
past-year initiates aged 12 to 49, the
average age at initiation in 2006 was
20.6 years.
MDMA Use by Students
2007 Monitoring the Future Survey
8th Grade 10th Grade 12th Grade
Lifetime †††
2.3%
5.2%
6.5%
Past Year
1.5
3.5
4.5
Past Month 0.6
1.2
1.6
August 2008
Page 3 of 4
423203676.026.png 423203676.027.png 423203676.028.png 423203676.029.png 423203676.030.png 423203676.031.png 423203676.032.png 423203676.033.png 423203676.034.png 423203676.035.png 423203676.036.png 423203676.037.png 423203676.038.png 423203676.039.png 423203676.040.png 423203676.041.png 423203676.042.png 423203676.043.png 423203676.044.png
For more information, please visit www.clubdrugs.org and www.teens.drugabuse.gov .
For street terms searchable by drug name, street term, cost and quantities, drug trade, and drug use, visit
www.whitehousedrugpolicy.gov/streetterms/default.asp .
†† These data are from the 2006 Monitoring the Future survey, funded by the National Institute on Drug Abuse,
National Institutes of Health, Department of Health and Human Services, and conducted annually by the University
of Michigan’s Institute for Social Research. The survey has tracked 12th-graders’ illicit drug use and related attitudes
since 1975; in 1991, 8th- and 10th-graders were added to the study. The latest data are online at
www.drugabuse.gov .
††† “Lifetime” refers to use at least once during a respondent’s lifetime. “Past year” refers to use at least once during
the year preceding an individual’s response to the survey. “Past month” refers to use at least once during the 30 days
preceding an individual’s response to the survey.
†††† NSDUH (formerly known as the National Household Survey on Drug Abuse) is an annual survey of Americans age
12 and older conducted by the Substance Abuse and Mental Health Services Administration. Copies of the latest sur-
vey are available at www.samhsa.gov and from NIDA at 877-643-2644.
References
1 Ricaurte GA, McCann UD. Experimental studies on 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its
potential to damage brain serotonin neurons. Neurotox Res 3(1):85–99, 2001.
2 Stone AL, Storr CL, Anthony JC. Evidence for a hallucinogen dependence syndrome developing soon after onset of
hallucinogen use during adolescence. Int J Methods Psychiatr Res 15:116–130, 2006.
3 Cottler LB, Womack SB, Compton WM, Ben-Abdallah A. Ecstasy abuse and dependence among adolescents and
young adults: Applicability and reliability of DSM-IV criteria. Human Psychopharmacol 16:599–606, 2001.
4 Leung KS, Cottler LB. Ecstasy and other club drugs: A review of recent epidemiological studies. Curr Opin Psychiatry
21:234–241, 2008.
5 Kraner JC, McCoy DJ, Evans MA, Evans LE, Sweeney BJ. Fatalities caused by the MDMA-related drug para-
methoxyamphetamine (PMA). J Anal Toxicol 25(7):645–648, 2001.
National Institutes of Health – U.S. Department of Health and Human Services
This material may be used or reproduced without permission from NIDA. Citation of the source is appreciated.
August 2008
Page 4 of 4
423203676.045.png 423203676.046.png 423203676.047.png 423203676.048.png 423203676.049.png 423203676.050.png 423203676.052.png 423203676.053.png 423203676.054.png 423203676.055.png 423203676.056.png 423203676.057.png 423203676.058.png 423203676.059.png 423203676.060.png 423203676.061.png 423203676.063.png 423203676.064.png 423203676.065.png
Zgłoś jeśli naruszono regulamin